Skip to main content

Table 4 Pilot outcomes

From: Sugammadex, neostigmine and postoperative pulmonary complications: an international randomised feasibility and pilot trial

Outcome

Estimate

(95% confidence interval)

p value

Primary outcome—adjudicated

 New pulmonary complications up to hospital discharge (or postoperative day 7 if still in hospital)

1.02 (0.28 to 3.67)

0.976

Secondary outcomes

 Duration of PACU stay (h)

0.20 (−0.07 to 0.47)

0.152

 PONV on postoperative day 1

0.80 (0.38 to 1.71)

0.565

 QoR-15 on postoperative day 1

−0.62 (−6.28 to 5.05)

0.830

 Days alive and at home on postoperative day 30

0.00 (−2.15 to 2.15)

1.000

 Frailty at 3 months postoperatively

1.68 (0.27 to 10.49)

0.579

  1. CFS Clinical Frailty Score, PACU post-anaesthesia care unit, PONV postoperative nausea and vomiting. QoR quality of recovery, Frailty CFS >4. Estimates of the treatment effect are presented as odds ratios (primary outcome, PONV and frailty), absolute mean (QoR-15) or absolute median (duration of PACU stay and days alive and at home on postoperative day 30) differences. All analyses are adjusted for site. Frailty and QoR-15 are also adjusted for preoperative values. Missing data: duration of PACU stay = 3 (2.5%), CFS at 3 months postoperatively = 4 (3.3%)